亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

北京萊瑞森醫(yī)藥科技有限公司  

醫(yī)藥原料藥和中間體,替莫唑胺、磷酸氟達(dá)拉濱、阿德福韋酯、阿米舒必利、鹽酸吉西他濱、培美曲塞二鈉、伏立康唑、法羅培南鈉、阿米酸、阿加曲班中間體.....

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:劉巧麗
  • 電話:86-010-80771378-8017
  • 郵件:lunarsunliu@hotmail.com
  • 傳真:010-80771338
  • QQ:873162955
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
首頁(yè) > 供應(yīng)產(chǎn)品 > 氫溴酸達(dá)非那新,CAS No:133099-07-7
氫溴酸達(dá)非那新,CAS No:133099-07-7
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 北京付款后3天內(nèi)
品牌 萊瑞森醫(yī)藥
型號(hào) 133099-07-7
規(guī)格 >95%
過期 長(zhǎng)期有效
更新 2012-03-26 21:07
 
詳細(xì)信息

中文名稱:氫溴酸達(dá)非那新
中文別名: {1-[2-(2,3-二氫苯并呋喃-5-基)乙基]-3-吡咯烷基}-2,2-二苯基乙酰胺氫溴酸鹽
CAS登錄號(hào):133099-07-7
英文名稱:Darifenacin hydrobromide
分子式:C28H30N2O2.HBR
分子量:507.47
©2025 北京萊瑞森醫(yī)藥科技有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:11192  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |